Disease relevance of Adenosine, N-cyclohexyl-

• We have demonstrated an accentuation of cannabinoid (CP55,940)-induced motor incoordination in mice by the adenosine A(1) receptor-selective agonist N(6)-cyclohexyladenosine (CHA) (4 ng) using an intracerebellar (ICB) microinjection method [1].
• The rank order of potency of inhibition of I(Ca) was N(6)-cyclohexyladenosine (CHA) > ADO > 2-(4-(2-carboxyethyl)phenylethylamino)adenosine-5'-N-ethylcarboxamideadenosine (CGS-21680) > N(6)-2-(4-aminophenyl)ethyladenosine (APNEA) [2].
• Characterization of N(6)-cyclohexyladenosine-induced hypothermia in Syrian hamsters [3].

Psychiatry related information on Adenosine, N-cyclohexyl-

• Adenosine A(1) receptor agonists N(6)-cyclohexyladenosine (CHA) or N(6)-phenylisopropyladenosine (R-PIA) only at the higher doses used, and adenosine A(2) receptor agonist 5'-N-ethylcarboxaminoadenosine (NECA), at all doses used, decreased morphine-induced amnesia in a dose-dependent manner [4].

High impact information on Adenosine, N-cyclohexyl-

• In in vitro experiments, porcine renal proximal tubular cells were incubated with 250 microM L-dopa and N(6)-cyclohexyladenosine, an adenosine type 1 receptor agonist, after treatment with adenosine deaminase [5].
• In primary HTM cells and the HTM-3 cell line, administration of the A(1) agonist N(6)-cyclohexyladenosine (CHA) produced a concentration-dependent increase in ERK1/2 activation [6].
• CHA (N(6)-cyclohexyladenosine) activated Gi, Gs and Gq, but was more efficacious than CPA in activating Gs [7].
• Moreover, the selective A(1) adenosine receptor agonist, N(6)-cyclohexyladenosine (CHA), did not induce any significant effect on cell viability [8].
• N(6)-cyclohexyladenosine (CHA) was used to selectively suppress adipocyte lipolysis during euglycemic clamps in conscious male dogs [9].

Chemical compound and disease context of Adenosine, N-cyclohexyl-

• Intracerebellar microinfusion of adenosine A(1) agonist, N(6)-cyclohexyladenosine (CHA: 4ng), and antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX: 100ng) markedly accentuated and attenuated, respectively, ethanol ataxia consistent with our previously published data [10].

Biological context of Adenosine, N-cyclohexyl-

• Relative to untreated hearts, N(6)-cyclohexyladenosine (CHA, 0.5 microM) improved post-ischaemic LV work (158%) and reduced glycolysis and proton production (53 and 42%, respectively) [11].
• 1 Injection of N(6)-cyclohexyladenosine (CHA; 1, 5 and 10 nmol), an adenosine A1 receptor agonist, into the posterior hypothalamus of rats produced a dose-dependent decrease in blood pressure (BP) and heart rate (HR) [12].

Anatomical context of Adenosine, N-cyclohexyl-

• In the fully kindled animals, N(6)-cyclohexyladenosine (CHA), a selective A(1) receptor agonist, and 1,3-dimethyl-8-cyclopenthylxanthine (CPT), a selective A(1) receptor antagonist, were microinjected bilaterally into the EC (group 1) or amygdala (group 2) [13].

Gene context of Adenosine, N-cyclohexyl-

• Systemic injection of the selective adenosine A1 receptor agonist, N(6)-cyclohexyladenosine (CHA; 0.3 mg/kg) resulted in a 49% reduction (P<0.05) in the magnitude of light-induced phase delays [14].

References